Plan a traceable Module 3 quality dossier

How do you plan a CTD Module 3 quality dossier?

Start with the actual drug substances, manufacturers, finished-product presentations and submission purpose. Map their quality evidence into the applicable substance, product, appendix and regional sections, with an owner and source for each claim. A complete electronic tree is not proof that the necessary CMC evidence exists.

Before you begin

FDA marketing dossiers using the displayed eCTD v4 hierarchy and M4Q(R1) organization. IND stage, special product classes and lifecycle changes need their own applicability assessment.

What you will prepare: A dossier map that identifies each substance, manufacturer, product presentation, evidence owner and unresolved applicability decision.

Freeze context before assigning sections

Start with the application pathway, submission purpose, product class, dosage forms, strengths, manufacturing sites and intended commercial process. M4Q(R1), page 5, describes organization; it explicitly does not establish the type and extent of all supporting data. Do not turn its table of contents into a mandatory experiment list or reuse a marketing dossier checklist unchanged for an early IND.

FDA labels M4Q(R2), January 2026, draft and not for implementation. Keep the current preparation map separate from an R2 readiness project. A future-looking diagram is not authority to change the submission structure today. If product classification or the applicable structure is unresolved, assign the question to the regulatory owner before creating filing commitments.

3.2.S and 3.2.P: model the actual dossier instances

For 3.2.S, create a record for each drug substance and identify which manufacturer's process each description represents. For a combination drug product, M4Q calls for the S information for each substance. A shared test method can be referenced, but that does not establish that two manufacturing routes have identical impurities or controls.

For 3.2.P, distinguish finished-product dosage form and composition from the substance. Record strengths, presentations, manufacturing process and container configurations. Assess any supplied reconstitution diluent; M4Q describes a separate P part as appropriate. Ask the CMC lead which information can be combined with a clear scope statement and which needs separate treatment. Never silently merge a tablet, solution and diluent because their brand name matches.

Build the evidence-to-section map

Use a working register with: section, dossier instance, source record and revision, scientific owner, planned narrative, dependency, and disposition. Mark an item applies, conditional, not applicable or undetermined with a reason. Keep that decision separate from whether the document is drafted or approved. These are editorial controls, not FDA status codes.

Route substance identity, manufacturing, characterization, controls, reference materials, packaging and stability to S.1–S.7. Route product composition, development, manufacture, excipients, controls, reference materials, packaging and stability to P.1–P.8. Appendices carry their specific cross-cutting evidence; R contains justified regional material; 3.3 holds cited literature. The Quality Overall Summary should draw its claims from the underlying dossier, not introduce missing results.

The FDA v4 hierarchy does not include a separate 3.1 placement in this snapshot. Likewise, S.1 nomenclature/structure/properties are useful narrative subdivisions rather than separate electronic nodes here. Confirm the publishing convention with the submission publisher instead of manufacturing a heading.

Worked review: two suppliers, one misleading summary

Fictional exercise: a tablet dossier names two API manufacturers, but its S.2 manufacturing narrative and S.3 impurity assessment cover only supplier A. The QOS says both sources are controlled identically.

Trace each supplier through the instance register, obtain supplier B's applicable process and impurity evidence or authorized reference, and reconcile the control strategy. Until that work is resolved, qualify the summary and mark B's coverage undetermined. Adding B's address to a table does not repair the missing science. Finish by checking that every QOS conclusion points to the intended substance/product instance and actual supporting record.

Build an instance register before assigning authors

Use this editorial register to prevent one apparently complete narrative from concealing another supplier, strength or package. A row represents a real scope of evidence, not simply a folder.

Assign two separate statuses to each row: applicability and preparation. “Applies, evidence pending” is different from “not applicable, rationale approved.” Combining both into a green completion marker can hide the most important unresolved work.

Planning exercise: a second strength uses a different coating and package. Do not duplicate the first strength's completed checklist and change its name. Ask which composition, performance, manufacturing and stability assessments carry over, and record the basis for each shared item. Link any distinct work to the affected section owners.

Write the QOS from this reconciled map after the underlying conclusions are established. Keep the regional-information assessment explicit: common CTD organization does not remove regional content conditions.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides